Incidence and prevalence of NMOSD in Australia and New Zealand.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bukhari Wajih, Prain Kerri M, Waters Patrick, Woodhall Mark, O'Gorman Cullen M, Clarke Laura, Silvestrini Roger A, Bundell Christine S, Abernethy David, Bhuta Sandeep, Blum Stefan, Boggild Mike, Boundy Karyn, Brew Bruce J, Brown Matthew, Brownlee Wallace J, Butzkueven Helmut, Carroll William M, Chen Celia, Coulthard Alan, Dale Russell C, Das Chandi, Dear Keith, Fabis-Pedrini Marzena J, Fulcher David, Gillis David, Hawke Simon, Heard Robert, Henderson Andrew P D, Heshmat Saman, Hodgkinson Suzanne, Jimenez-Sanchez Sofia, Killpatrick Trevor, King John, Kneebone Christopher, Kornberg Andrew J, Lechner-Scott Jeannette, Lin Ming-Wei, Lynch Christpher, Macdonell Richard, Mason Deborah F, McCombe Pamela A, Pender Michael P, Pereira Jennifer A, Pollard John D, Reddel Stephen W, Shaw Cameron, Spies Judith, Stankovich James, Sutton Ian, Vucic Steve, Walsh Michael, Wong Richard C, Yiu Eppie M, Barnett Michael H, Kermode Allan G, Marriott Mark P, Parratt John D E, Slee Mark, Taylor Bruce V, Willoughby Ernest, Wilson Robert J, Vincent Angela, Broadley Simon A
Аннотация
BACKGROUND: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established.
METHODS: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture-recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases.
RESULTS: NMOSD was confirmed in 81/170 (48%) cases referred. Capture-recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD.
CONCLUSIONS: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.